Kymera Therapeutics Inc. (KYMR)
| Bid | 32.87 |
| Market Cap | 2.25B |
| Revenue (ttm) | 47.07M |
| Net Income (ttm) | -223.86M |
| EPS (ttm) | -2.98 |
| PE Ratio (ttm) | -11.62 |
| Forward PE | -8.35 |
| Analyst | Buy |
| Ask | 35.01 |
| Volume | 380,026 |
| Avg. Volume (20D) | 713,639 |
| Open | 34.04 |
| Previous Close | 34.27 |
| Day's Range | 32.85 - 34.88 |
| 52-Week Range | 19.45 - 53.27 |
| Beta | 2.23 |
About KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation ...
Analyst Forecast
According to 13 analyst ratings, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is $57, which is an increase of 64.57% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call TranscriptKymera Therapeutics, Inc. (NASDAQ:KYMR ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Justine Koenigsberg - Vice President-Investor Relations Nello Mainolfi - Fou...
